Jibon Kotoky

Jibon Kotoky

Auto-generated profile, based on publicly available information

Jibon Kotoky

Drug Discovery lab, Institute of Advanced Study in Science and Technology, Guwahati, Assam, India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
Raghuram KandimallaRaghuram Kandimalla
Raghuram Kandimalla
SKSanjeeb Kalita
Sanjeeb Kalita
BCBhaswati Choudhury
Bhaswati Choudhury
DDDipali Devi
Dipali Devi
DKDhaneswar Kalita
Dhaneswar Kalita
JKJibon Kotoky
Jibon Kotoky

1 April 2016 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
SKSanjeeb Kalita
Sanjeeb Kalita
Raghuram KandimallaRaghuram Kandimalla
Raghuram Kandimalla
KSKaustav Kalyan Sharma
Kaustav Kalyan Sharma
AKAmal Chandra Kataki
Amal Chandra Kataki
MDManab Deka
Manab Deka
JKJibon Kotoky
Jibon Kotoky

31 October 2016 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
VMV. L. Maruthanila
V. L. Maruthanila
Elancheran RamakrishnanElancheran Ramakrishnan
Elancheran Ramakrishnan
AKA. B. Kunnumakkara
A. B. Kunnumakkara
SKS. Kabilan
S. Kabilan
JKJibon Kotoky
Jibon Kotoky

29 January 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
BCBhaswati Choudhury
Bhaswati Choudhury
Raghuram KandimallaRaghuram Kandimalla
Raghuram Kandimalla
RBRupjyoti Bharali
Rupjyoti Bharali
JMJavadi Monisha
Javadi Monisha
AKAjaikumar B. Kunnumakara
Ajaikumar B. Kunnumakara
JKJibon Kotoky
Jibon Kotoky
Traditional knowledge (TK) based medicines have gained worldwide attention and presently the scientific community is focussing on proper pharmacological validation and identification of lead compounds for the treatment of various diseases. The North East region of India is the home of valuable traditional herbal remedies. Garcinia morella Desr. (Guttiferae) is one such medicinal plant used by traditional healers for the treatment of inflammatory disorders. The present study was aimed to evaluate the antioxidant and anticancer activity of methanol extracts of the leaf, bark and fruit of G. morella (GM) in different in vitro and in vivo experimental conditions. The results of this study showed that GM methanol extracts possessed in vitro antioxidant and anticancer properties, where the fruit extract (GF) showed maximum activity. The anticancer activity was further confirmed by the results of in vivo administration of GF (200 mg/kg) for ten days to Dalton's Lymphoma (DLA) induced mice. GF extract significantly increased the mean survival time (MST) of the animals, decreased the tumour volume and restored the haematological and biochemical parameters. The present study for the first time reported the anticancer property of GF on DLA. Further from the experiments conducted to elucidate the mechanism of action of GF on DLA, it can be concluded that GF exerts its anticancer effect through induction of caspases and DNA fragmentation that ultimately leads to apoptosis. However further experimentation is required to elucidate the active principle and validate these findings in various in vivo settings.

1 April 2015 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JKJibon Kotoky
Jibon Kotoky
Raghuram KandimallaRaghuram Kandimalla
Raghuram Kandimalla
SKSanjeeb Kalita
Sanjeeb Kalita
BDBanasmita Devi
Banasmita Devi
KSKaustav Kalyan Sharma
Kaustav Kalyan Sharma
AKAmal Chandra Kataki
Amal Chandra Kataki
Chloramphenicol encapsulated in poly-ε-caprolactone–pluronic composite: nanoparticles for treatment of MRSA-infected burn wounds Sanjeeb Kalita,1 Banasmita Devi,1 Raghuram Kandimalla,1 Kaustav Kalyan Sharma,1 Arup Sharma,2 Kasturi Kalita,3 Amal Chandra Kataki,4 Jibon Kotoky1 1Institute of Advanced Study in Science and Technology (IASST), Division of Life Sciences, Paschim Boragaon, Garchuk, Guwahati, Assam, India; 2College of Veterinary Science, Assam Agriculture University, Khanapara, Guwahati, Assam, India; 3Hyat Hospital, Lalganesh, Guwahati, Assam, India; 4Dr B Borooah Cancer Institute, Guwahati, Assam, India The emergence of methicillin-resistant Staphylococcus aureus (MRSA) infection has increased precipitously over the past several decades, with far-reaching health care and societal costs. MRSA infections in the context of burn wounds lead to invasive disease that could potentially cause mortality. Chloramphenicol is a well-known broad-spectrum bacteriostatic antibiotic that has been used since 1949, but due to its hydrophobicity, poor penetration in skin, fast degradation, and toxicity, its application has been hindered. Furthermore, it has been demonstrated that old antibiotics such as chloramphenicol remained active against a large number of currently prevalent resistant bacterial isolates due to their low-level use in the past. Recently, the novel nanoparticulate drug-delivery system has been used and reported to be exceptionally useful for topical therapeutics, due to its distinctive physical characteristics such as a high surface-to-volume ratio and minuscule size. It helps to achieve better hydrophilicity, bioavailability, and controlled delivery with enhanced therapeutic index, which has resulted in decreased toxicity levels compared to the crude drug. Here, we report a novel chloramphenicol loaded with poly(ε-caprolactone) (PCL)-pluronic composite nanoparticles (CAM-PCL-P NPs), physicochemical characterizations, and its bioactivity evaluation in a MRSA-infected burn-wound animal model. CAM-PCL-P NPs could encapsulate 98.3% of the drug in the nanoparticles and release 81% of the encapsulated drug over 36 days with a time to 50% drug release of 72 hours (51%). Nanoparticle suspensions maintained the initial properties with respect to size and encapsulation efficiency, even after 6 months of storage at 4°C and 25°C, respectively (P>0.05). Significant reduction in the level of toxicity was observed for CAM-PCL-P NPs compared with that of free drug as confirmed from hemolytic activity against human blood erythrocytes and cytotoxicity assay against an MCF-7 breast cancer cell line. In vitro antibacterial activities were performed by zone of inhibition, minimum inhibitory concentrations, minimum bacterial concentration, and time-kill assays, which showed that CAM-PCL-P NPs exhibited significantly enhanced anti-MRSA activity against ten clinical isolates of MRSA strains. The augmented activity of CAM-PCL-P NPs was further tested on a MRSA-infected burn-wound animal model and achieved quicker efficacy in MRSA clearance and improved the survival rate compared with free-chloramphenicol treatment. Thus, we propose CAM-PCL-P NPs as a promising novel antimicrobial candidate that may have a good potential for preclinical applications. Keywords: chloramphenicol, PCL-pluronic, nanoparticle, methicillin-resistant Staphylococcus aureus, anti-MRSA activity, burn-wound animal model

30 June 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Raghuram KandimallaRaghuram Kandimalla
Raghuram Kandimalla
SKSANJEEB Kalita
SANJEEB Kalita
BCBhaswati Choudhury
Bhaswati Choudhury
SDSuvakanta Dash
Suvakanta Dash
KKKasturi Kalita
Kasturi Kalita
JKJibon Kotoky
Jibon Kotoky
Poor wound healing is one of the major complication of diabetic patients which arises due to different factors like hyperglycemia, oxidative stress, vascular insufficiency and microbial infections. Candidiasis of diabetic wounds is a difficult to treat condition and potentially can lead to organ amputation. There are a few number of medications available in market to treat this chronic condition; which demands for alternative treatment options. In traditional system of medicine like Ayurveda, essential oil extracted from leaves of Cymbopogon nardus L. (Poaceae) has been using for the treatment of microbial infections, inflammation and pain. In this regard, we have evaluated anti-Candida and anti-inflammatory activity mediated wound healing property of C. nardus essential oil (EO-CN) on candidiasis of diabetic wounds. EO-CN was obtained through hydro-distillation and subjected to Gas chromatography mass spectroscopy (GC-MS) analysis for chemical profiling. Anti-Candida activity of EO-CN was tested against C. albicans, C. glabrata and C. tropicalis by in-vitro zone of inhibition and minimum inhibitory concentration (MIC) assays. Anti-candidiasis ability of EO-CN was evaluated on C. albicans infected diabetic wounds of mice through measuring candida load on the 7th, 14th and 21st day of treatment. Further progression in wound healing was confirmed by measuring the inflammatory marker levels and histopathology of wounded tissues on last day of EO-CN treatment. A total of 95 compounds were identified through GC-MS analysis, with major compounds like citral, 2,6-octadienal- 3,7-dimethyl-, geranyl acetate, citronellal, geraniol and citronellol. In vitro test results demonstrated strong anti-Candida activity of EO-CN with a MIC value of 25 µg/ml against C. albicans, 50 µg/ml against C. glabrata and C. tropicalis. EO-CN treatment resulted in significant reduction of candida load on diabetic wounds. Acceleration in wound healing was indicated by declined levels of inflammatory cytokines at wounded area in EO-CN treated animals compared to non-treated group, which was further confirmed by histopathological examination. This study suggests that through significant anti-Candida and anti-inflammatory activity, EO-CN attenuates the growth of the fungus on diabetic wounds and simultaneously reduces the inflammation which leads to acceleration of the wound healing process.